Merck's stock rallies toward a record after FDA OKs arterial-hypertension drugMarket Watch • 03/27/24
FDA Approves Merck's WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)Business Wire • 03/26/24
Merck's Cardiovascular 'Renaissance' Is Here With The First Approval Of A $10 Billion FranchiseInvestors Business Daily • 03/26/24
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer StudyZacks Investment Research • 03/22/24
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerBusiness Wire • 03/21/24
Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson's Digital Biomarkers Observational StudyBusiness Wire • 03/20/24
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsBusiness Wire • 03/19/24
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformPRNewsWire • 03/15/24
Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerBusiness Wire • 03/15/24
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9Business Wire • 03/13/24
Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 03/12/24
Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered BiologicsBusiness Wire • 03/12/24
Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript)Seeking Alpha • 03/11/24